Market revenue in 2023 | USD 471.1 million |
Market revenue in 2030 | USD 935.2 million |
Growth rate | 10.3% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | BD, Danaher Corp, Koninklijke Philips NV, Qiagen NV, Thermo Fisher Scientific Inc, Myriad Genetics Inc, Argon Medical Devices, Roche Holding AG ADR, Hologic Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to breast cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 64.04% in 2023. Horizon Databook has segmented the Japan breast cancer diagnostics market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
Japan’s proportion of geriatric population is increasing rapidly, wherein both life expectancy & per capita income among the population aged 80 and above are high. According to Japan’s Ministry of health Labour and Welfare, cancer is a major cause of death, contributing to around 30% of total deaths. Aging has become a leading risk factor for numerous diseases, including breast cancer.
These factors are accelerating market growth in this region. In addition, presence of key market players such as Hologic, Inc.; Koninklijke Philips N.V.; and Danaher are undertaking initiatives to promote personalized medicines in primary care testing, closer to patients.
According to Roswell Park Comprehensive Cancer Centre, in 2017, 1 out of every 38 women is estimated to be diagnosed with breast cancer in Japan. High adoption of western lifestyle and diet among youth contribute to the high incidence of the disease in Japan.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan breast cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Japan breast cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account